Wegovy denials: what the review data shows
Independent reviewers have decided 606 published cases where an insurer denied Wegovy — and they overturned the insurer 88.6% of the time. A denial for Wegovy is a starting position, not a final answer.
By condition
| Condition | Decisions | Overturned |
|---|---|---|
| Obesity | 486 | 90.7% |
| Endocrine/metabolic | 18 | 66.7% |
| Diabetes Mellitus | 18 | 100% |
Why plans deny Wegovy — and how appeals win
Wegovy (semaglutide) is FDA-approved for: chronic weight management; reducing the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with established cardiovascular disease and overweight or obesity. Denials that treat an on-label prescription as unproven or cosmetic are the ones reviewers reverse most readily.
Plan-level weight-loss drug exclusion
Many employer plans exclude the entire “weight-loss drug” benefit category. The denial letter says “not a covered benefit” rather than anything about you. That framing is beatable when the prescription targets a diagnosed condition — obesity is a chronic disease, and Wegovy also carries a cardiovascular indication that has nothing to do with cosmetic weight loss.
BMI documentation gaps
Plans that do cover Wegovy typically require chart-documented BMI plus, at lower BMI levels, a weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, and similar). Denials often turn on the chart not showing the numbers — not on the numbers being wrong.
Step therapy
Plans commonly demand documented failure of a structured lifestyle program or an older, cheaper weight-loss medication first. Reviewers routinely accept a physician's account of prior attempts and reasons alternatives are inappropriate.
Quantity limits and dose-titration denials
Wegovy is titrated stepwise to a maintenance dose. Refill and dose-change requests sometimes get denied as exceeding quantity limits mid-titration — a plumbing problem dressed up as a coverage decision.
If the plan demands you try something else first, request a step-therapy exception: your prescriber attests to prior failures, contraindications, or clinical reasons the preferred alternative is inappropriate. Most states and plan types have a formal exception process with short decision deadlines.
What winning Wegovy appeals argue
- Frame obesity as the chronic disease the diagnosis codes say it is — the appeal is about treating a diagnosed condition, not “lifestyle.”
- If cardiovascular disease is in the picture, put the cardiovascular-risk indication front and center: a plan cannot call an FDA-approved cardiac-risk-reduction use cosmetic.
- Document every prior weight-management attempt — programs, medications, outcomes — to preempt the step-therapy rationale.
- Ask the plan for the exact exclusion or criteria language cited; denials that cannot quote plan language tend not to survive review.
The published record backs the effort: 606 external-review decisions on Wegovy denials, 88.6% overturned. For the full class-wide picture — cross-indication strategy, exclusion language, and the record for every GLP-1 drug — see the GLP-1 denial appeal guide.
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Wegovywhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY